Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KALA BIO, Inc. (NASDAQ: KALA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into KALA’s clinical-stage biopharmaceutical business focused on rare and severe eye diseases, its mesenchymal stem cell secretome (MSC-S) platform, and its evolving financial and strategic position.
Through KALA’s annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review information on research and development activities, pipeline programs such as KPI-012 and KPI-014, risk factors, liquidity and capital resources. Current Reports on Form 8-K highlight material events, including the CHASE Phase 2b trial results for KPI-012, decisions to cease development of KPI-012 and the MSC-S platform, workforce reductions, financing agreements, loan defaults and settlements with Oxford Finance LLC, and Nasdaq listing deficiency notices.
KALA’s filings also include transaction-related documents, such as the Securities Purchase Agreement for Series AA and Series AAA convertible preferred stock, the Convertible Loan Agreement with an investor, and the Oxford Loan Settlement Agreement. These records explain how the company has structured recent financings, addressed debt obligations and framed its exploration of strategic alternatives. Notifications like Form 12b-25 describe timing of periodic reports when delays occur.
On Stock Titan, KALA filings are updated in near real time as they appear on EDGAR. AI-powered summaries help interpret lengthy 10-K and 10-Q reports, breaking down key sections on clinical programs, cash runway, going-concern language and risk disclosures. For Form 4 and other insider-related filings, users can quickly see reported insider transactions in KALA stock. This combination of raw filings and AI-generated explanations allows readers to understand what each document means for KALA’s business, capital structure and potential strategic direction without having to parse every page manually.
Kala Bio Chief Business Officer Darius Kharabi reported a sale of 4,511 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (ranging from $3.87 to $4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 16, 2021.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Kharabi maintains beneficial ownership of 62,566 shares, including 28,878 unvested RSUs
- The transaction was executed as a direct ownership sale
- The Form 4 was filed through an attorney-in-fact on June 26, 2025
This planned sale under Rule 10b5-1 demonstrates standard executive equity management for tax obligations rather than a discretionary trading decision.
Kala Bio CFO Mary Reumuth reported a sale of 3,631 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 9, 2020.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Reumuth maintains beneficial ownership of 62,100 shares, including 28,906 unvested RSUs
- The transaction was reported via Form 4 within the required filing deadline
This planned sale under Rule 10b5-1 demonstrates standard executive equity management practices for tax obligations and does not indicate a significant change in the CFO's overall position in the company.
Kala Bio insider Todd Bazemore, serving as Interim CEO, President and COO, reported a transaction on June 24, 2025 involving the sale of 4,058 shares of common stock at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details of the transaction:
- Sale was executed under a 10b5-1 trading plan established on November 10, 2020
- Purpose: Cover tax withholding obligations related to RSU vesting from June 22, 2023 grant
- Post-transaction holdings: 83,699 shares (including 35,732 unvested RSUs) held directly
- Additional indirect ownership: 1 share held by son
The transaction was reported via Form 4 filing, signed by Mary Reumuth as attorney-in-fact on June 26, 2025, complying with SEC disclosure requirements for insider trading activity.
Kala Bio insider trading activity reported: Head of Research and Development and Chief Medical Officer Romulus K. Brazzell sold 5,251 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details:
- Sale executed under a 10b5-1 trading plan established November 9, 2020
- Transaction purpose: Cover tax withholding obligations from RSU vesting granted June 22, 2023
- Post-transaction holdings: 82,698 shares, including 35,952 unvested RSUs
- Transaction form: Direct ownership
The sale was made in compliance with SEC regulations and followed a pre-established trading plan, indicating a routine transaction rather than a strategic investment decision.
Kala Bio (NASDAQ:KALA) filed a routine Form 4 reporting that director Mark T. Iwicki sold 13,227 common shares on June 24 2025 at a weighted-average price of $4.01 per share, generating roughly $53 000 in gross proceeds.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9 2020 to cover tax-withholding obligations related to the vesting of restricted stock units (RSUs) granted on June 22 2023.
After the sale, Iwicki retains 258 433 shares, including 103 540 unvested RSUs, meaning the disposition represents slightly under 5 % of his prior beneficial ownership. No changes to company operations, strategy, or financial condition are disclosed.
Form 144 Notice of Proposed Sale filed for Kala Bio (NASDAQ: KALA) indicates an insider's intent to sell 5,251 shares of common stock with an aggregate market value of $21,056.51 through E*TRADE Financial Corporation. The planned sale is scheduled for June 24, 2025.
The securities being sold were originally acquired through a Restricted Stock Unit (RSU) vesting on June 24, 2025, where the insider received 16,450 shares as equity compensation. The total shares outstanding for Kala Bio are reported at 6,452,398.
Recent trading activity by the same seller through E*TRADE includes a previous sale of 3,687 shares on June 3, 2025, which generated gross proceeds of $13,789.38. This Form 144 filing represents the seller's declaration that they are not aware of any material adverse non-public information regarding the company.
KALA BIO, Inc. has filed a Form 144 indicating a proposed sale of 3,631 shares of its common stock. The shares are to be sold through E*TRADE Financial on or after 24 June 2025 on the NASDAQ exchange. At the reference market price, the transaction is valued at approximately $14,560. The company reports 6,452,398 shares outstanding, so the contemplated sale represents roughly 0.06% of the float.
The shares were acquired via the vesting of Restricted Stock Units (RSUs) issued as equity compensation on the same date. During the past three months, the same account sold 2,850 shares on 3 June 2025 for gross proceeds of $10,659.
Rule 144 filings are routine administrative notices required before certain affiliate or insider sales. Given the small size relative to total shares and the absence of any disclosed adverse information, the filing appears immaterial to the company’s fundamentals and is unlikely to influence trading dynamics.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
